GlassScriptPhysician profile
Ketan G Laud
NPI 1114151537
$289,658.48
in general payments reported to CMS, 2019-2025
33 companies · $67K in 2025
The $67K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,746 · 2021: $1,258 · 2022: $77K · 2023: $29K · 2024: $96K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Food and Beverage: $8,432 · Travel and Lodging: $5,394 · Honoraria: $4,725 · Consulting Fee: $3,800 · Education: $116 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,355.00 |
| Food and Beverage | $8,432.09 |
| Travel and Lodging | $5,393.51 |
| Honoraria | $4,725.00 |
| Consulting Fee | $3,800.00 |
| Education | $115.83 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $216,481.32 | 2020-2025 | Acthar |
| Astellas Pharma US INC | $43,828.74 | 2023-2025 | Izervay |
| Genentech USA, INC. | $18,468.53 | 2019-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $5,274.48 | 2022-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Regeneron Healthcare Solutions, INC. | $1,716.21 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $572.10 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $454.71 | 2022-2025 | Xipere, Vyzulta, Visudyne |
| Mallinckrodt Enterprises LLC | $357.98 | 2019 | |
| Alimera Sciences, INC. | $259.23 | 2021-2024 | Iluvien, Yutiq |
| Allergan, INC. | $232.72 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $228.89 | 2022-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $194.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $190.46 | 2019-2021 | |
| Eyepoint US, INC. | $190.08 | 2020-2023 | |
| Oculus Surgical INC. | $182.83 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $156.70 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $121.48 | 2024-2025 | Iheezo, Vevye |
| Sun Pharmaceutical Industries INC. | $104.96 | 2021-2025 | Cequa |
| Coherus Oncology, INC. | $98.05 | 2022-2023 | |
| Alcon Vision LLC | $93.31 | 2022-2024 | Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.47 | 2021 | |
| Oyster Point Pharma, INC. | $80.45 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $79.75 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $44.14 | 2024 | Eylea Hd |
| Horizon Therapeutics Plc | $39.10 | 2019-2023 | Tepezza |
| Biotissue Holdings INC. | $25.89 | 2023 | |
| Beaver-Visitec International, INC. | $22.96 | 2023 | |
| Shire North American Group INC | $18.99 | 2019 | |
| Thea Pharma INC. | $16.65 | 2023 | |
| Amgen INC. | $16.62 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $14.03 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketan Laud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.